Health
FDA lifts clinical hold on Intellia's CRISPR Phase 3 trial
Intellia Therapeutics (NASDAQ:NTLA) announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on its MAGNITUDE-2 Phase 3 clinical trial.
United StatesHealth
Health
HCA Healthcare profit surges 30% as patient admissions drive record quarter
HCA Healthcare (NYSE:HCA) delivered a powerful finish to 2025, reporting a 30.6% surge in fourth-quarter net income as the largest U.S. hospital operator capitalized on rising patient demand and stabilized labor costs.
Health
UnitedHealth Group caps 2025 with $447B in revenue
UnitedHealth Group (NYSE:UNH) announced its full-year 2025 results on Tuesday, reporting consolidated revenues of $447.6 billion—a 12% increase year-over-year.
Health
Neurocrine advances next-gen VMAT2 candidate for tardive dyskinesia
Neurocrine Biosciences (NASDAQ:NBIX) announced on January 26, 2026, the initiation of its Phase 2 clinical study for NBI-1065890, an investigational compound targeting tardive dyskinesia (TD).
Health
Milestone Pharmaceuticals debuts Cardamyst nasal spray in U.S. retail market
Milestone Pharmaceuticals (NASDAQ:MIST) has officially moved into the commercial stage with the U.S. retail launch of Cardamyst™ (etripamil).
Health
SciSparc diversifies into medical devices with MUSE endoscopy deal
SciSparc (NASDAQ:SPRC), a company traditionally focused on cannabinoid-based pharmaceuticals, has officially pivoted into the medical device sector.
Health
Mirum Pharmaceuticals clinches Bluejay acquisition to lead in rare liver disease
Mirum Pharmaceuticals (NASDAQ:MIRM) announced the successful closing of its acquisition of Bluejay Therapeutics, a move that significantly broadens its rare disease pipeline with a potential first-in-class therapy for chronic hepatitis delta virus (HDV).
Health
United Therapeutics bioengineered liver passes initial human safety test
United Therapeutics (NASDAQ:UTHR) has cleared a primary safety hurdle in its ambitious effort to manufacture biological alternatives to human organs, reporting that its bioengineered external liver supported critically ill patients without serious adverse effects.
Health
MannKind gains FDA nod for Afrezza dosing guide
MannKind (NASDAQ:MNKD) received U.S. Food and Drug Administration approval on Monday for a critical update to the prescribing information for Afrezza, its inhaled mealtime insulin.
Health
FDA grants priority review to Biogen and Eisai’s at-home Alzheimer’s injectable
Biogen (NASDAQ:BIIB) and Eisai have cleared a significant regulatory hurdle as the U.S. Food and Drug Administration (FDA) accepted their supplemental Biologics License Application for a subcutaneous version of the Alzheimer’s treatment Leqembi.
Health
Bausch Health liver drug fails to meet main goal in Phase 3 trial
Bausch Health Companies (NYSE:BHC) today announced results from its global Phase 3 RED-C clinical program evaluating amorphous-rifaximin SSD for the primary prevention of hepatic encephalopathy (HE) in adults with liver cirrhosis.
Health
Sanara MedTech issues preliminary 2025 revenue of $103M
Sanara MedTech (NASDAQ:SMTI) announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, along with initial guidance for 2026.